Jan 20 (Reuters) - AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq ...

AstraZeneca could build a new six-storey block at Cambridge Biomedical Campus (CBC) to house offices and a conference centre.

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. AstraZeneca PLC is placed fourth on our list among the ...

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house ...

To get full control of C-CAR031, AZ is buying out AbelZeta's 50% share of the China development and commercialisation rights ...

By Maggie Fick SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on ...